Cargando…

Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model

Detalles Bibliográficos
Autores principales:	Sola, Caroline, Chanuc, Fabien, Thielens, Ariane, Fuseri, Nicolas, Morel, Yannis, Bléry, Mathieu, André, Pascale, Vivier, Eric, Graziano, Robert, Romagne, Francois, Bonnafous, Cécile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/ http://dx.doi.org/10.1186/2051-1426-1-S1-P40

Ejemplares similares

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
por: Vey, Norbert, et al.
Publicado: (2018)

S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS
por: Demaria, Olivier, et al.
Publicado: (2023)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

Targeting MICA with therapeutic antibodies for the treatment of cancer
por: Bonnafous, Cécile, et al.
Publicado: (2013)

Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T cell lymphomas
por: Marie-Cardine, Anne, et al.
Publicado: (2013)

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control
por: Bléry, Mathieu, et al.
Publicado: (2021)

Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition
por: Liu, Hongli, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death
por: Masum, Abdullah-Al, et al.
Publicado: (2018)

Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
por: van Agthoven, Ton, et al.
Publicado: (2015)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
por: Morales-Estevez, Cristina, et al.
Publicado: (2016)

Ligilactobacillus salivarius 2102-15 complete genome sequence data
por: Karlyshev, Andrey V., et al.
Publicado: (2023)

Natural killer cell-based therapies
por: Romagné, François, et al.
Publicado: (2011)

Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients
por: Vergori, Alessandra, et al.
Publicado: (2021)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
por: Rottey, Sylvie, et al.
Publicado: (2022)

IPhO: list of winners in 1st-40th international physics olympiads
por: Gorzkowski, Waldemar, et al.
Publicado: (2010)

Genomics is changing personal healthcare and medicine: the dawn of iPH (individualized preventive healthcare)
por: Mehrian-Shai, Ruty, et al.
Publicado: (2015)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

2102. Peripherally Inserted Central Catheter (PICC) Placement: Indications and Financial Impact
por: Cheronis, Nicholas, et al.
Publicado: (2018)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
por: Mayer, Lloyd, et al.
Publicado: (2014)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors
por: Nokihara, Hiroshi, et al.
Publicado: (2012)

The importance of cell culture parameter standardization: an assessment of the robustness of the 2102Ep reference cell line
por: Kusena, James Willard Tonderai, et al.
Publicado: (2021)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity
por: Imamura, Michie, et al.
Publicado: (2020)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Prevalence of stroke in Pakistan: Findings from Khyber Pakhtunkhwa integrated population health survey (KP-IPHS) 2016-17
por: Sherin, Akhtar, et al.
Publicado: (2020)

Long-Term Exposure to Particulate Matter and Mortality from Cardiovascular Diseases in Japan: The Ibaraki Prefectural Health Study (IPHS)
por: Takeuchi, Ayano, et al.
Publicado: (2021)

Diabetes Mellitus Modifies the Association of Serum Triglycerides with Ischemic Cardiovascular Disease Mortality: The Ibaraki Prefectural Health Study (IPHS)
por: Yamagishi, Kazumasa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9kbr1nd5hcv61lep7di8h1oi4p